

Reference number(s)
1841-A

SPECIALTY GUIDELINE MANAGEMENT

COPAXONE (glatiramer acetate) GLATOPA (glatiramer acetate) glatiramer acetate

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

For the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

A. Relapsing forms of multiple sclerosis

Authorization of 12 months may be granted to members who have been diagnosed with a relapsing form of multiple sclerosis (including relapsing-remitting and secondary progressive disease for those who continue to experience relapse).

B. Clinically isolated syndrome

Authorization of 12 months may be granted to members for the treatment of clinically isolated syndrome of multiple sclerosis.

III. CONTINUATION OF THERAPY

For all indications: Authorization of 12 months may be granted for members who are experiencing disease stability or improvement while receiving Copaxone, Glatopa, or glatiramer acetate.

IV. OTHER CRITERIA

Members will not use Copaxone, Glatopa, or glatiramer acetate concomitantly with other disease modifying multiple sclerosis agents (Note: Ampyra and Nuedexta are not disease modifying).

V. REFERENCES

1. Copaxone [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; July 2020.
2. Glatopa [package insert]. Princeton, NJ: Sandoz Inc.; July 2020.
3. Glatiramer acetate [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; September 2020.

Reference number(s)
1841-A

4. IBM Micromedex [database online]. Ann Arbor, MI: IBM Watson Health. Updated periodically. www.micromedexsolutions.com [available with subscription]. April 13, 2021.
5. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed April 13, 2021.
6. The Multiple Sclerosis Coalition. *The use of disease-modifying therapies in multiple sclerosis: principles and current evidence*. http://www.nationalmssociety.org/getmedia/5ca284d3-fc7c-4ba5-b005-ab537d495c3c/DMT_Consensus_MS_Coalition_color. Accessed May 01, 2019.